SavedAdd your journal

Journals / Balkan Medical Journal / 2022 / Cilt: 39 - Sayı: 3

Antibiotic use and Influencing Factors Among Hospitalized Patients with COVID-19: A Multicenter Point-Prevalence Study from Turkey

İrfan ŞENCAN
Yasemin ÇAĞ
Oğuz KARABAY
Behice KURTARAN
Ertuğrul GÜÇLÜ
Aziz ÖĞÜTLÜ
Zehra DEMİRBAŞ
Dilek BULUT
Gülden Eser KARLIDAĞ
Merve Sefa SAYAR
Ezgi Gizem ŞİBAR
Oya Özlem EREN KUTSOYLU
Gülnur KUL
Serpil EROL
Begüm BEKTAŞ
Tülay ÜNVER ULUSOY
Semanur KUZİ
Meltem TASBAKAN
Özge YİĞİT
Pages
209–217
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: A total of 1500 patients hospitalized with a diagnosis of

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Broad-spectrum empirical antimicrobials are frequently prescribed for patients with coronavirus disease 2019 (COVID-19) despite the lack of evidence for bacterial coinfection.
📊
Key Findings & Data:Aims: We aimed to cross-sectionally determine the frequency of antibiotics use, type of antibiotics prescribed, and the factors influencing antibiotics use in hospitalized patients with COVID-19 confirmed by polymerase chain reaction.
💡
Conclusion & Impact:Results: A total of 1500 patients hospitalized with a diagnosis of
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Background: Broad-spectrum empirical antimicrobials are frequently prescribed for patients with coronavirus disease 2019 (COVID-19) despite the lack of evidence for bacterial coinfection. Aims: We aimed to cross-sectionally determine the frequency of antibiotics use, type of antibiotics prescribed, and the factors influencing antibiotics use in hospitalized patients with COVID-19 confirmed by polymerase chain reaction. Study Design: The study was a national, multicenter, retrospective, and single-day point prevalence study. Methods: This was a national, multicenter, retrospective, and single- day point-prevalence study, conducted in the 24-h period between 00:00 and 24:00 on November 18, 2020, during the start of the second COVID-19 peak in Turkey. Results: A total of 1500 patients hospitalized with a diagnosis of

🔖

Cite This Article

ŞENCAN, İ., ÇAĞ, Y., KARABAY, O., KURTARAN, B., GÜÇLÜ, E., ÖĞÜTLÜ, A., DEMİRBAŞ, Z., BULUT, D., KARLIDAĞ, G. E., SAYAR, M. S., ŞİBAR, E. G., KUTSOYLU, O. Ö. E., KUL, G., EROL, S., BEKTAŞ, B., ULUSOY, T. Ü., KUZİ, S., TASBAKAN, M., YİĞİT, Ö. (2022). Antibiotic use and Influencing Factors Among Hospitalized Patients with COVID-19: A Multicenter Point-Prevalence Study from Turkey. Balkan Medical Journal, Cilt: 39 - Sayı: 3, 209–217. https://ajindex.com/articles/460749

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and Fungal Coinfection in Individuals with Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020
  2. [CrossRef] 2. Joseph C, Togawa Y, Shindo N. Bacterial and viral infections associated with influenza. Influenza Other Respir Viruses. 2013
  3. 7 Suppl 2:105-13. [CrossRef] 3. Beovic B, Dousak M, Ferreira-Coimbra J, et al. Antibiotic use in patients with COVID-19: A “snapshot” Infectious Diseases International Research Initiative (ID- IRI) survey. J Antimicrob Chemother. 2020
  4. [CrossRef] 4. Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect. 2021
  5. [CrossRef] 5. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020
  6. [CrossRef] 6. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020
  7. [CrossRef] 7. Turkey Coronavirus: 3,745,657 Cases and 33,454 Deaths - Worldometer n.d. https:// www.worldometers.info/coronavirus/country/turkey/ (accessed April 10, 2021). 8. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19- Final Report. N Engl J Med. 2020
  8. [CrossRef] 9. Garcia-Vidal C, Sanjuan G, Moreno-García E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021
  9. [CrossRef] 10. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020
  10. [CrossRef] 11. Sepulveda J, Westblade LF, Whittier S, et al. Bacteremia and blood culture utilization during covid-19 surge in New York City. J Clin Microbiol. 2020
  11. [CrossRef] 12. Wang L, Amin AK, Khanna P, et al. An observational cohort study of bacterial co- infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London. J Antimicrob Chemother. 2021
  12. [CrossRef] 13. Karami Z, Knoop BT, Dofferhoff ASM, et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results